Clear Harbor Asset Management LLC Has $1.03 Million Holdings in Revolution Medicines, Inc. $RVMD

Clear Harbor Asset Management LLC raised its holdings in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) by 61.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,110 shares of the company’s stock after acquiring an additional 8,394 shares during the quarter. Clear Harbor Asset Management LLC’s holdings in Revolution Medicines were worth $1,033,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Nextech Invest Ltd. grew its position in Revolution Medicines by 20.7% during the fourth quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock valued at $332,472,000 after purchasing an additional 1,304,347 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Revolution Medicines by 6.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 109,004 shares of the company’s stock valued at $3,870,000 after acquiring an additional 6,877 shares in the last quarter. Millennium Management LLC grew its holdings in shares of Revolution Medicines by 681.8% during the 1st quarter. Millennium Management LLC now owns 156,353 shares of the company’s stock valued at $5,529,000 after acquiring an additional 136,353 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Revolution Medicines by 14.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 300,196 shares of the company’s stock worth $10,615,000 after acquiring an additional 37,345 shares during the last quarter. Finally, Intech Investment Management LLC raised its holdings in shares of Revolution Medicines by 48.8% during the first quarter. Intech Investment Management LLC now owns 107,628 shares of the company’s stock worth $3,806,000 after acquiring an additional 35,300 shares in the last quarter. 94.34% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

RVMD has been the topic of a number of recent research reports. Raymond James Financial boosted their target price on Revolution Medicines from $72.00 to $76.00 and gave the company a “strong-buy” rating in a research note on Friday, October 17th. Wedbush reissued an “outperform” rating on shares of Revolution Medicines in a research note on Friday. HC Wainwright raised their price objective on shares of Revolution Medicines from $72.00 to $73.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. UBS Group upgraded shares of Revolution Medicines to a “strong-buy” rating in a research note on Thursday, December 4th. Finally, National Bankshares set a $80.00 price target on shares of Revolution Medicines in a research note on Friday, October 17th. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Revolution Medicines presently has a consensus rating of “Buy” and a consensus target price of $78.94.

Insiders Place Their Bets

In other news, insider Mark A. Goldsmith sold 15,394 shares of Revolution Medicines stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $76.82, for a total value of $1,182,567.08. Following the transaction, the insider directly owned 232,469 shares in the company, valued at approximately $17,858,268.58. The trade was a 6.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Stephen Michael Kelsey sold 5,447 shares of the stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $76.82, for a total value of $418,438.54. Following the sale, the insider owned 278,600 shares of the company’s stock, valued at approximately $21,402,052. The trade was a 1.92% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 268,792 shares of company stock valued at $20,971,240. 8.20% of the stock is owned by company insiders.

Revolution Medicines News Summary

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Reports that Merck is in talks to acquire Revolution Medicines for roughly $30–32 billion, a direct M&A bid narrative that can justify a sizable takeover premium and is the primary driver of today’s rally. Merck in talks (WSJ)
• Positive Sentiment: Takeover buzz broadened as media reported additional suitors and renewed buyout interest (markets often bid target stocks higher on competing-acquirer speculation). Takeover buzz, another suitor emerges (Barron’s)
• Positive Sentiment: FDA granted Breakthrough Therapy Designation to zoldonrasib for KRAS G12D-mutant NSCLC — a substantive clinical/regulatory win that strengthens RVMD’s strategic value to acquirers and supports a higher acquisition valuation. Breakthrough Therapy Designation (GlobeNewswire)
• Positive Sentiment: Unusual options activity — a large spike in call buying — indicates aggressive bullish/speculative positioning by traders ahead of or on takeover rumors, amplifying short-term upside momentum. (market reports)
• Neutral Sentiment: The stock experienced a temporary LULD (limit up/limit down) pause during trading, a procedural volatility-control measure that often accompanies sudden price moves but does not change fundamentals.
• Negative Sentiment: Earlier takeover reports referenced AbbVie interest but AbbVie publicly denied talks, which previously triggered volatility and a pullback — a reminder that rumor-driven moves can reverse if potential bidders decline to engage. AbbVie denies talks (Barron’s)
• Negative Sentiment: Revolution remains a loss-making biotech (recent quarterly EPS missed estimates), so absent a takeover premium the stock’s valuation relies on successful late-stage clinical outcomes and eventual commercialization. (company filings/earnings)

Revolution Medicines Trading Up 10.5%

NASDAQ:RVMD opened at $118.64 on Friday. The company’s 50 day moving average is $76.36 and its 200-day moving average is $53.98. The company has a quick ratio of 8.05, a current ratio of 8.05 and a debt-to-equity ratio of 0.16. Revolution Medicines, Inc. has a 12 month low of $29.17 and a 12 month high of $121.62. The firm has a market cap of $22.94 billion, a price-to-earnings ratio of -22.95 and a beta of 0.99.

Revolution Medicines (NASDAQ:RVMD) last posted its earnings results on Wednesday, November 5th. The company reported ($1.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.39) by ($0.22). During the same quarter last year, the business posted ($0.94) EPS. Equities analysts anticipate that Revolution Medicines, Inc. will post -3.49 EPS for the current year.

Revolution Medicines Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.